Assembly Biosciences to present hepatitis delta drug data at EASL congress

May 13, 2026 2:00 AM

Assembly Biosciences Inc. (NASDAQ: ASMB) announced it will present topline Phase 1a clinical data on ABI-6250, an investigational oral hepatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found